H1 secures $40M from CVS, proving SaaS startups can still attract investment

H1 secures $40M from CVS, proving SaaS startups can still attract investment | TechCrunch

–:–:–:–

The first StrictlyVC of 2026 hits SF on April 30. Tickets are going fast. Register now.

Get Disrupt Early Bird savings of up to $410 by May 29, 11:59 p.m. PT. Register now.

Image Credits:H1 Startups

H1 secures $40M from CVS, proving SaaS startups can still attract investment

Marina Temkin

11:08 AM PDT · May 28, 2026

It’s no secret that pre-AI era startups are generally getting little love from investors now.

Ariel Katz, co-founder and CEO of a nine-year-old healthcare data platform H1, argues that not all SaaS companies should be painted with the same broad brush.

“If you’re a workflow SaaS company, you could vibe code that,” he told TechCrunch. What AI cannot easily replicate, according to Katz, is a company that is a data provider at its core.

That’s a self-serving viewpoint — H1’s entire business is built on selling detailed information about doctors to pharma companies, hospital systems, and health insurers — but it doesn’t mean he is wrong.

“I don’t worry about Claude ever doing what we do,” Katz said, referring to Anthropic’s popular AI model. He thinks that the data H1 collects on physicians globally could actually be so valuable to AI model makers that they are more likely to become customers than competitors.

CVS Health Ventures, the corporate venture capital arm of the CVS/Aetna health giant, must agree that H1 is in no danger of becoming a victim of the “SaaSocalypse.” The investor just led a $40 million round into H1.

H1 wasn’t looking to raise capital, Katz said. The startup turned cash flow and EBITDA profitable last year and is forecasting to grow over 40% this year. But the partnership with one of the largest healthcare companies in the world was hard to refuse, Katz said.

Despite the strong financial fundamentals, companies like H1 aren’t exciting for traditional VCs who are currently consumed with backing AI startups at skyrocketing valuations.

H1 was last valued at $750 million when it raised $100 million in funding led by Altimeter Capital at the height of the Covid-era tech bubble in November of 2021.

Like other companies that secured capital just before valuations plummeted in 2022, H1 has focused on becoming profitable. The startup has also grown through acquiring smaller competitors and complementary businesses.

Topics Biotech & Health, CVS Health Ventures, Fundraising, h1, health data, Startups

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Marina Temkin

Reporter, Venture

Marina Temkin is a venture capital and startups reporter at TechCrunch. Prior to joining TechCrunch, she wrote about VC for PitchBook and Venture Capital Journal. Earlier in her career, Marina was a financial analyst and earned a CFA charterholder designation. You can contact or verify outreach from Marina by emailing marina.temkin@techcrunch.com or via encrypted message at +1 347-683-3909 on Signal.

View Bio

October 13-15 San Francisco Early Bird ticket savings of up to $410 end May 29, 11:59 p.m. PT. Connect with 10,000+ tech leaders in unparalleled networking, 200+ hands-on sessions led by 250+ industry leaders, and discover 300+ showcasing startups.